Conference Coverage

Drinking beet juice tied to reduced post-PCI restenosis


 

AT CRT 2023

WASHINGTON – Late lumen loss (LLL) after percutaneous interventions (PCI) can be reduced significantly by a daily glass of beet juice, according to a phase 2 randomized trial.

The protection against LLL, attributed to the nitrate contained in beet juice, was accompanied by a trend for a reduced risk of major adverse cardiovascular events (MACE), according to Krishnaraj Rathod, MBBS, BMedSci, PhD, who presented results at the Cardiovascular Research Technologies conference, sponsored by MedStar Heart & Vascular Institute.

The study grew out of relatively recent evidence that ingestion of nitrate-rich foods, such as beets, can trigger noncanonical pathways for nitric oxide generation, sometimes referred to as the nitrate-nitrite-nitric oxide sequence. Dr. Rathod cited experimental evidence associating this pathway with the traditional benefits of NO generation, such as anti-inflammatory and antithrombotic effects.

Dr. Krishnaraj Rathod of Barts Heart Centre, London Ted Bosworth/MDedge News

Dr. Krishnaraj Rathod

In this study, 300 patients scheduled for PCI to treat stable angina were randomized to the experimental arm of nitrate-rich beetroot juice or the control arm of nitrate-depleted beetroot juice. Each had a 70-mL glass of juice once daily. Dr. Rathod, a senior interventional cardiology registrar, Barts Heart Centre, London, described this as the equivalent of about four beets.

The primary endpoint of the study was in-stent LLL assessed by quantitative coronary angiography (QCA) at 6 months.

MACE, defined as death, MI, need for revascularization, and in-stent thrombosis, was assessed at 3, 9, 12, and 24 months. In addition, markers of NO activation, platelet reactivity, and inflammation were monitored.

Lumen loss reduced less than 50%

On OCA, the median stent LLL at 6 months was 0.244 mm in the nitrate-depleted beet juice group and 0.117 mm (P = .0165) in the group that received natural beet juice. The mean segment LLL similarly favored the natural beet juice (0.269 vs. 0.050 mm; P = .0011).

The same effect was reflected in the measurement of mean change in minimum lumen diameter at 6 months. From baseline, this in-stent measure was reduced at 6 months by 0.244 mm in the control group, but by only 0.117 mm in the group receiving the dietary nitrate (P = .0154 for two-way analysis of variance).

Over 24 months of follow-up, there were 18 MACE events in the control arm versus 9 in the arm randomized to dietary nitrate (P = .0718). There were no in-stent thromboses observed in either group, but death (two vs. five), MI (one vs. six), and target-vessel revascularization (six vs. seven) were all numerically lower in the group receiving dietary nitrate.

“Once-a-day oral dietary nitrate for 6 months was well tolerated and safe,” Dr. Rathod reported at the meeting.

Asked specifically about the taste of the daily glass of beet juice, Dr. Rathod acknowledged that some patients were not enamored, but many had no objections or even liked the taste.

The patients were reasonably representative of a PCI population. The mean age in both groups was 61 years. There were no significant differences in body mass index (approximately 29 kg/m2) or proportion with diabetes (22%), hypertension, or hypercholesterolemia (about 70% in both groups) and other comorbidities.

More PCI was performed in the left anterior descending artery (36.7% vs. 44.0%) in the control group, while less PCI was performed in the right coronary (27.3% vs. 30.7%). Neither difference was significant. The vast majority (~90%) of patients received drug-eluting stents with a mean of 1.4 implanted. Procedural success was 100% in both groups.

Discharge medications, including antiplatelet and antithrombotic therapies, were similar in the two groups.

Pages

Recommended Reading

Simulation-based training effective for transesophageal echo
MDedge Cardiology
Damar Hamlin’s cardiac arrest: Key lessons
MDedge Cardiology
STS, new president apologize for predecessor’s speech amid Twitter backlash
MDedge Cardiology
CV deaths jumped in 2020, reflecting pandemic toll
MDedge Cardiology
Legacy ICDs exposed to MRI still shock, pace as needed
MDedge Cardiology
Three wild technologies about to change health care
MDedge Cardiology
What happened to surgical mitral valve repair in the MitraClip era?
MDedge Cardiology
Guidance for PCI without on-site surgical backup updated
MDedge Cardiology
Steak dinners, sales reps, and risky procedures: Inside the big business of clogged arteries
MDedge Cardiology
New ACC, AHA, SCAI interventional cardiology training guidance
MDedge Cardiology